About Artiva Biotherapeutics, Inc.
https://www.artivabio.comArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
CEO
Fred Aslan
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:9.85M
Value:$47.1M
5AM VENTURE MANAGEMENT, LLC
Shares:2.35M
Value:$11.25M
VR ADVISER, LLC
Shares:1.61M
Value:$7.69M
Summary
Showing Top 3 of 42
About Artiva Biotherapeutics, Inc.
https://www.artivabio.comArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $22.23M ▼ | $-21.53M ▼ | 0% | $-0.88 ▼ | $-20.87M ▲ |
| Q2-2025 | $0 | $22.81M ▲ | $-21.25M ▼ | 0% | $-0.87 ▼ | $-22.17M ▼ |
| Q1-2025 | $0 | $22.17M ▲ | $-20.31M ▼ | 0% | $-0.83 ▼ | $-21.54M ▼ |
| Q4-2024 | $0 | $18.27M ▼ | $-9.21M ▲ | 0% | $-0.82 ▲ | $-17.65M ▲ |
| Q3-2024 | $0 | $18.34M | $-17.47M | 0% | $-0.92 | $-17.71M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $122.97M ▼ | $148.86M ▼ | $19.64M ▼ | $129.22M ▼ |
| Q2-2025 | $142.37M ▼ | $169.39M ▼ | $20.35M ▼ | $149.04M ▼ |
| Q1-2025 | $165.96M ▼ | $191.26M ▼ | $22.48M ▼ | $168.78M ▼ |
| Q4-2024 | $185.43M ▲ | $209.58M ▼ | $22.94M ▼ | $186.64M ▼ |
| Q3-2024 | $146.63M | $225.6M | $24.6M | $201M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-21.53M ▼ | $-19.2M ▲ | $16.28M ▼ | $-37K ▲ | $-2.96M ▼ | $-19.8M ▲ |
| Q2-2025 | $-21.25M ▼ | $-22.98M ▼ | $21.12M ▲ | $-72K ▼ | $-1.93M ▲ | $-24.04M ▼ |
| Q1-2025 | $-20.31M ▼ | $-19.84M ▼ | $9.97M ▲ | $239K ▲ | $-9.63M ▲ | $-20.35M ▼ |
| Q4-2024 | $-16.09M ▲ | $-14.65M ▼ | $-966K ▲ | $-30K ▼ | $-15.65M ▼ | $-14.71M ▼ |
| Q3-2024 | $-17.47M | $-11.61M | $-130.63M | $163.87M | $21.63M | $-11.71M |
CEO
Fred Aslan
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:9.85M
Value:$47.1M
5AM VENTURE MANAGEMENT, LLC
Shares:2.35M
Value:$11.25M
VR ADVISER, LLC
Shares:1.61M
Value:$7.69M
Summary
Showing Top 3 of 42